Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bellus Health Inc (BLU.TO)

Bellus Health Inc (BLU.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,470,301
  • Shares Outstanding, K 126,812
  • Annual Sales, $ 16 K
  • Annual Income, $ -76,080 K
  • 60-Month Beta -0.02
  • Price/Sales 118,424.40
  • Price/Cash Flow N/A
  • Price/Book 5.07
Trade BLU.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.73
  • Most Recent Earnings $-0.20 on N/A
  • Next Earnings Date 08/09/23
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.29
  • Low Estimate -0.32
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -34.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.10 +1.99%
on 06/15/23
19.88 -2.01%
on 05/31/23
-0.21 (-1.07%)
since 05/29/23
3-Month
8.58 +127.04%
on 04/05/23
19.90 -2.11%
on 05/25/23
+9.61 (+97.37%)
since 03/29/23
52-Week
8.58 +127.04%
on 04/05/23
19.90 -2.11%
on 05/25/23
+6.54 (+50.54%)
since 06/29/22

Most Recent Stories

More News
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...

BLU : 14.74 (unch)
GSK.LN : 1,599.000 (-1.17%)
GSK : 40.48 (-0.69%)
BLU.TO : 19.48 (-0.10%)
Bellus: Q1 Earnings Snapshot

Bellus: Q1 Earnings Snapshot

BLU.TO : 19.48 (-0.10%)
BELLUS Health Announces Meeting Updates

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“ BELLUS Health ” or the “ Company ”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough,...

BLU : 14.74 (unch)
BLU.TO : 19.48 (-0.10%)
Stocks Start out Downward

Equities in Toronto declined at the open on Wednesday as miners and oil companies tracked commodity ...

BLU.TO : 19.48 (-0.10%)
Stocks in play: BELLUS Health Inc

Announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, ...

BLU.TO : 19.48 (-0.10%)
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical...

BLU : 14.74 (unch)
GSK : 40.48 (-0.69%)
GSK.LN : 1,599.000 (-1.17%)
BLU.TO : 19.48 (-0.10%)
GSK signs deal to buy Canadian drug developer Bellus Health for US$2 billion

TORONTO — GSK plc has announced a deal to buy Canadian drug developer Bellus Health Inc. for US$2 billion.

BLU.TO : 19.48 (-0.10%)
TSX Finds Strength at Daily Close, Venture Down on Week

Stocks remained volatile in Canada’s biggest market, but fought their way to positive reading Thursday, ...

BLU.TO : 19.48 (-0.10%)
Stocks in play: BELLUS Health Inc.

Announced positive data from its Phase 1 bioavailability equivalence study evaluating a once-daily Extended-Release ...

BLU.TO : 19.48 (-0.10%)
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough,...

BLU : 14.74 (unch)
BLU.TO : 19.48 (-0.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, a P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business...

See More

Key Turning Points

3rd Resistance Point 20.02
2nd Resistance Point 19.81
1st Resistance Point 19.65
Last Price 19.48
1st Support Level 19.28
2nd Support Level 19.07
3rd Support Level 18.91

See More

52-Week High 19.90
Last Price 19.48
Fibonacci 61.8% 15.58
Fibonacci 50% 14.24
Fibonacci 38.2% 12.90
52-Week Low 8.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar